Free Trial
NASDAQ:TSVT

2seventy bio Q4 2024 Earnings Report

2seventy bio logo
$5.00 0.00 (0.00%)
As of 05/13/2025

2seventy bio EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

2seventy bio Revenue Results

Actual Revenue
$2.93 million
Expected Revenue
$12.84 million
Beat/Miss
Missed by -$9.91 million
YoY Revenue Growth
N/A

2seventy bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
11:30AM ET

Upcoming Earnings

2seventy bio's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Friday, August 8, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

2seventy bio Earnings Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More 2seventy bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 2seventy bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 2seventy bio and other key companies, straight to your email.

About 2seventy bio

2seventy bio (NASDAQ:TSVT) is a clinical-stage biotechnology company focused on the discovery, development and manufacturing of engineered cell therapies for the treatment of cancer. The company’s proprietary platforms leverage both autologous and allogeneic approaches to address solid tumors and hematologic malignancies. Through a multi-modality pipeline, 2seventy bio aims to expand the reach of cell-based immunotherapies beyond current indications, harnessing T cell receptors (TCRs), chimeric antigen receptors (CARs) and natural killer (NK) cells.

The company’s lead programs include TCR-T cell candidates targeting well-characterized tumor antigens such as NY-ESO-1 and MAGE-A4, as well as next-generation CAR-T constructs designed to overcome tumor microenvironment barriers. In parallel, 2seventy bio is developing off-the-shelf NK cell therapies engineered for enhanced persistence and cytotoxicity. Its integrated manufacturing network supports both clinical supply and scalable commercial production, enabling efficient translation from discovery to late-stage trials.

2seventy bio was formed through a business combination in 2022 and is headquartered in Cambridge, Massachusetts, with additional research and development facilities in Seattle and Europe. The company maintains active clinical trial programs across North America, Asia and Europe, collaborating with leading academic centers and oncology consortia. This global footprint aims to accelerate patient access to innovative cell therapy candidates and generate robust clinical data in diverse patient populations.

Under the leadership of President and CEO Charles J. Wilson, Ph.D., 2seventy bio leverages decades of experience in cell therapy research and development. The executive team includes seasoned industry veterans in manufacturing, regulatory affairs and clinical development, fostering strategic partnerships with pharmaceutical companies and academic institutions. Together, they are committed to advancing next-generation cell therapies that address unmet medical needs in oncology.

View 2seventy bio Profile

More Earnings Resources from MarketBeat